Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 11/09/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Invesco Pharmaceuticals ETF

PJP | ETF

$129.68

$582 M

0.93%

$1.21

0.58%

Vitals

YTD Return

25.0%

1 yr return

33.1%

3 Yr Avg Return

24.9%

5 Yr Avg Return

11.0%

Net Assets

$582 M

Holdings in Top 10

53.7%

52 WEEK LOW AND HIGH

$126.8
$99.78
$131.64

Expenses

OPERATING FEES

Expense Ratio 0.58%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 48.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 11/09/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Invesco Pharmaceuticals ETF

PJP | ETF

$129.68

$582 M

0.93%

$1.21

0.58%

PJP - Profile

Distributions

  • YTD Total Return 25.0%
  • 3 Yr Annualized Total Return 24.9%
  • 5 Yr Annualized Total Return 11.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.76%
DIVIDENDS
  • Dividend Yield 0.9%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    Invesco Pharmaceuticals ETF
  • Fund Family Name
    INVESCOETF
  • Inception Date
    Jun 23, 2005
  • Shares Outstanding
    4200000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Hubbard

Fund Description

div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt"The Fund is an index fund that seeks/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"to track the investment results of the/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"Underlying Index./spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /span/div div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; margin-left:15pt"Strictly in accordance with its guidelines and mandated procedures, ICE /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"Data Indices, LLC (“ICE Data” or the “Index Provider”) compiles and maintains the Underlying Index, which is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. In accordance with the Underlying Index methodology, the various types of companies may include companies from the following segments of the pharmaceutical industry:/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /span/divtable cellpadding="0" style="line-height: 11pt; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;"tr style="vertical-align: top; text-align: justify" td style="width: 0.25in"/tdtd style="width: 0.25in; text-align: left"span style="color: #000000; font-family: Arial Narrow; font-size: 10pt"■ /span/tdtd style="text-align: left"span style="font-family: Arial Narrow; font-size: 10pt; color: #000000"Big Pharmaceutical: Large, vertically integrated drug companies that actively participate in all major phases of the drug development process, including research and development, animal and human testing, manufacturing and sales and marketing./span/td /tr/tabletable cellpadding="0" style="line-height: 11pt; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;"tr style="vertical-align: top; text-align: justify" td style="width: 0.25in"/tdtd style="width: 0.25in; text-align: left"span style="color: #000000; font-family: Arial Narrow; font-size: 10pt"■ /span/tdtd style="text-align: left"span style="font-family: Arial Narrow; font-size: 10pt; color: #000000"Specialty Pharmaceutical: Midsize, often vertically integrated drug companies specializing in one or two therapeutic areas using both traditional chemical techniques and biotechnological techniques (involving living organisms, cells, and/or components of cells) to develop drugs./span/td /tr/tabletable cellpadding="0" style="line-height: 11pt; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;"tr style="vertical-align: top; text-align: justify" td style="width: 0.25in"/tdtd style="width: 0.25in; text-align: left"span style="color: #000000; font-family: Arial Narrow; font-size: 10pt"■ /span/tdtd style="text-align: left"span style="font-family: Arial Narrow; font-size: 10pt; color: #000000"Generic Pharmaceutical: Generally midsize to small non-vertically integrated drug companies that actively participate only in the manufacturing and sometimes sales and marketing of patent-expired drugs./span/td /tr/table div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; margin-left:15pt"As of June 30, /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"2026, the Underlying Index was comprised of 28/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"constituents with market capitalizations ranging from $1.2/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"billion to $1.1/spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"trillion./spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt; line-height:11pt" /span/div div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; margin-left:15pt"The Fund employs a “full replication” methodology in seeking to track /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"the Underlying Index, meaning that the Fund generally invests in all of the securities comprising the Underlying Index in proportion to their weightings in the Underlying Index./span/div div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; margin-left:15pt"The Fund is “non-diversified” and therefore is not required to meet /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"certain diversification requirements under the  Investment Company Act of 1940, as amended (the “1940 Act”)./span/divdiv style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; margin-left:15pt"In accordance with Rule 35d-1 under the 1940 Act, the Fund has /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"adopted a policy to invest, under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in the pharmaceuticals industry, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in the pharmaceuticals industry (the “80% investment policy”). For purposes of the 80% investment policy, the Fund considers the components of the Underlying Index to be securities of companies engaged in the pharmaceuticals industry./span/div div style="line-height:11.0pt; text-align:left"span style="color:#000000; font-family:Arial Narrow; font-size:10pt; font-style:italic; margin-left:15pt"Concentration Policy. /spanspan style="color:#000000; font-family:Arial Narrow; font-size:10pt"The Fund will concentrate its investments (i.e., invest 25% or more of the value of its total assets) in securities of issuers in any one industry or group of industries only to the extent that the Underlying Index reflects a concentration in that industry or group of industries. The Fund will not otherwise concentrate its investments in securities of issuers in any one industry or group of industries. As of April 30, 2026, the Fund had significant exposure to the pharmaceuticals and biotechnology industries. The Fund’s portfolio holdings, and the extent to which it concentrates its investments, are likely to change over time./span/div
Read More

PJP - Performance

Return Ranking - Trailing

Period PJP Return Category Return Low Category Return High Rank in Category (%)
YTD 25.0% -5.4% 67.1% 18.18%
1 Yr 33.1% -4.7% 74.8% 24.68%
3 Yr 24.9%* 4.9% 38.7% 14.29%
5 Yr 11.0%* -8.0% 15.5% 9.74%
10 Yr 9.2%* 5.8% 14.3% 84.38%

* Annualized

Return Ranking - Calendar

Period PJP Return Category Return Low Category Return High Rank in Category (%)
2025 26.5% -21.9% 61.0% 14.29%
2024 8.6% -28.2% 8.6% 0.65%
2023 -3.2% -8.6% 18.9% 86.36%
2022 -3.1% -53.9% 3.2% 7.79%
2021 13.6% -39.6% 24.2% 12.99%

Total Return Ranking - Trailing

Period PJP Return Category Return Low Category Return High Rank in Category (%)
YTD 25.0% -5.4% 67.1% 18.18%
1 Yr 33.1% -4.7% 74.8% 24.68%
3 Yr 24.9%* 4.9% 38.7% 14.29%
5 Yr 11.0%* -8.0% 15.5% 9.74%
10 Yr 9.2%* 5.8% 14.3% 84.38%

* Annualized

Total Return Ranking - Calendar

Period PJP Return Category Return Low Category Return High Rank in Category (%)
2025 28.0% -0.5% 63.7% 20.78%
2024 9.6% -28.2% 9.9% 1.30%
2023 -2.2% -8.6% 18.9% 93.51%
2022 -2.2% -53.9% 3.7% 12.34%
2021 14.6% -33.9% 26.0% 28.57%

PJP - Holdings

Concentration Analysis

PJP Category Low Category High PJP % Rank
Net Assets 582 M 8.74 M 49.1 B 62.99%
Number of Holdings 33 24 423 94.16%
Net Assets in Top 10 253 M 3.68 M 25 B 61.69%
Weighting of Top 10 53.65% 14.3% 79.5% 20.13%

Top 10 Holdings

  1. Invesco Private Prime Fund 7.93%
  2. Abbott Laboratories 5.67%
  3. AbbVie Inc. 5.48%
  4. Amgen Inc. 5.33%
  5. Johnson Johnson 5.18%
  6. Merck Co., Inc. 5.06%
  7. Eli Lilly and Co. 5.02%
  8. Corcept Therapeutics Inc. 4.96%
  9. Gilead Sciences, Inc. 4.53%
  10. Pfizer Inc. 4.50%

Asset Allocation

Weighting Return Low Return High PJP % Rank
Stocks 		99.92% 83.24% 106.13% 10.39%
Cash 		11.76% 0.00% 30.28% 5.84%
Preferred Stocks 		0.00% 0.00% 7.86% 94.16%
Other 		0.00% -22.99% 6.91% 87.66%
Convertible Bonds 		0.00% 0.00% 0.37% 92.86%
Bonds 		0.00% 0.00% 12.39% 94.16%

Stock Sector Breakdown

Weighting Return Low Return High PJP % Rank
Healthcare 		100.00% 71.19% 100.00% 44.16%
Utilities 		0.00% 0.00% 0.00% 92.86%
Technology 		0.00% 0.00% 2.45% 94.16%
Real Estate 		0.00% 0.00% 5.89% 94.16%
Industrials 		0.00% 0.00% 1.34% 94.81%
Financial Services 		0.00% 0.00% 1.60% 96.10%
Energy 		0.00% 0.00% 0.00% 92.86%
Communication Services 		0.00% 0.00% 0.69% 92.86%
Consumer Defense 		0.00% 0.00% 25.73% 94.81%
Consumer Cyclical 		0.00% 0.00% 0.82% 94.16%
Basic Materials 		0.00% 0.00% 7.16% 95.45%

Stock Geographic Breakdown

Weighting Return Low Return High PJP % Rank
US 		99.92% 63.26% 104.41% 8.44%
Non US 		0.00% 0.00% 32.76% 96.10%

PJP - Expenses

Operational Fees

PJP Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.58% 0.08% 4.23% 83.77%
Management Fee 0.50% 0.03% 1.25% 18.18%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

PJP Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

PJP Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A N/A N/A N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PJP Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 48.00% 1.00% 238.00% 47.45%

PJP - Distributions

Dividend Yield Analysis

PJP Category Low Category High PJP % Rank
Dividend Yield 0.93% 0.00% 6.24% 26.62%

Dividend Distribution Analysis

PJP Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Annual Annual

Net Income Ratio Analysis

PJP Category Low Category High PJP % Rank
Net Income Ratio 0.76% -2.27% 1.85% 10.53%

Capital Gain Distribution Analysis

PJP Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

PJP - Fund Manager Analysis

Managers

Peter Hubbard

Start Date

Tenure

Tenure Rank

Jun 01, 2007

15.01

15.0%

Peter Hubbard, Vice President and Director of Portfolio Management of the Invesco PowerShares Capital Management LLC. Mr. Hubbard has been a Portfolio Manager of the Adviser since June 2007 and has been associated with the Adviser since 2005. Prior to joining the Invesco PowerShares Capital Management LLC, Hubbard was a research analyst and trader for Ritchie Capital from September 2003 to May 2005.

Michael Jeanette

Start Date

Tenure

Tenure Rank

Aug 30, 2008

13.76

13.8%

Michael Jeanette, Senior Portfolio Manager of Invesco Capital Management LLC, has been associated with Invesco Capital Management LLC since 2008. Prior to joining Invesco Capital Management LLC, Mr. Jeanette was a trust advisor and GM of Chicago based Richard Lamb, LLC from 1998 to 2007.

Tony Seisser

Start Date

Tenure

Tenure Rank

Aug 29, 2014

7.76

7.8%

Tony Seisser is a Vice President and Portfolio Manager of Invesco PowerShares Capital Management LLC since December 2013. Prior to joining the Adviser, he was employed by Guggenheim Funds Distributors, Inc. where he was a trader from 2010 to 2013. Prior to that, Mr. Seisser was a compliance investigator at the Chicago Board of Options Exchange and Chicago Futures Exchange from 2008 to 2010.

Pratik Doshi

Start Date

Tenure

Tenure Rank

Aug 28, 2020

1.76

1.8%

Pratik Doshi is a Portfolio Manager of Invesco Capital Management. Mr. Doshi has been a Portfolio Manager of Invesco Capital Management since October 2019 and has been associated with Invesco Capital Management since 2018. Prior to joining Invesco Capital Management, Mr. Doshi was a business student in the MBA program at the University of Chicago from 2016 to 2018. From 2014 to 2016, he served as a Vice President at Bank of America, and from 2007 to 2014 he served as Assistant Vice President at Barclays Capital.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.25 24.72 8.34 22.1

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.